Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States

Deborah Persaud, Paul Palumbo, Carrie Ziemniak, Jie Chen, Stuart Campbell Ray, Michael Hughes, Peter Havens, Murli Purswani, Aditya H. Gaur, Ellen Gould Chadwick

Research output: Contribution to journalArticle

Abstract

Background. The extent to which drug-resistant human immunodeficiency virus type 1 (HIV-1) acquired through mother-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservoirs and limits responses to antiretroviral treatment in infants is unknown. Methods. We evaluated the presence, type, and persistence of drug-resistant HIV-1 in pretreatment plasma and resting CD4+ T cells from US infants enrolled in a multicenter, open-label, phase 1/2 treatment trial of lopinavir/ritonavir (Pediatric AIDS Clinical Trials Group Protocol 1030) in young infants. Results. Twenty-two consecutively enrolled infants initiating highly active antiretroviral therapy at a median age of 9.7 weeks and treated for up to 96 weeks were studied. Drug-resistant HIV-1 was present in 5 (23.8%) of 21 infants analyzed; 4 (80.0%) had nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1, only 1 of whom had a history of receiving nevirapine chemoprophylaxis. All 4 infants had NNRTI-resistant variants other than the K103N mutation. The fifth infant had the M184V mutation. Drug-resistant virus was archived in the resting CD4 + T cell latent reservoir in all 5 infants. Conclusions. The high rate, types, and early archiving of drug-resistant HIV-1 suggests that resistance testing be considered for infants, especially when an NNRTI-based regimen is planned. Furthermore, drug-resistance outcomes in infants should be an important secondary end point in MTCT trials.

Original languageEnglish (US)
Pages (from-to)1402-1410
Number of pages9
JournalJournal of Infectious Diseases
Volume195
Issue number10
DOIs
StatePublished - May 15 2007

Fingerprint

Reverse Transcriptase Inhibitors
HIV-1
Pharmaceutical Preparations
Chemoprevention
Mothers
Lopinavir
T-Lymphocytes
Nevirapine
Ritonavir
Mutation
Highly Active Antiretroviral Therapy
Clinical Protocols
Drug Resistance
Acquired Immunodeficiency Syndrome
Clinical Trials
Pediatrics
Viruses

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. / Persaud, Deborah; Palumbo, Paul; Ziemniak, Carrie; Chen, Jie; Ray, Stuart Campbell; Hughes, Michael; Havens, Peter; Purswani, Murli; Gaur, Aditya H.; Chadwick, Ellen Gould.

In: Journal of Infectious Diseases, Vol. 195, No. 10, 15.05.2007, p. 1402-1410.

Research output: Contribution to journalArticle

Persaud, Deborah ; Palumbo, Paul ; Ziemniak, Carrie ; Chen, Jie ; Ray, Stuart Campbell ; Hughes, Michael ; Havens, Peter ; Purswani, Murli ; Gaur, Aditya H. ; Chadwick, Ellen Gould. / Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. In: Journal of Infectious Diseases. 2007 ; Vol. 195, No. 10. pp. 1402-1410.
@article{bbd54fd022c24d71959e6f8bb120cc67,
title = "Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States",
abstract = "Background. The extent to which drug-resistant human immunodeficiency virus type 1 (HIV-1) acquired through mother-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservoirs and limits responses to antiretroviral treatment in infants is unknown. Methods. We evaluated the presence, type, and persistence of drug-resistant HIV-1 in pretreatment plasma and resting CD4+ T cells from US infants enrolled in a multicenter, open-label, phase 1/2 treatment trial of lopinavir/ritonavir (Pediatric AIDS Clinical Trials Group Protocol 1030) in young infants. Results. Twenty-two consecutively enrolled infants initiating highly active antiretroviral therapy at a median age of 9.7 weeks and treated for up to 96 weeks were studied. Drug-resistant HIV-1 was present in 5 (23.8{\%}) of 21 infants analyzed; 4 (80.0{\%}) had nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1, only 1 of whom had a history of receiving nevirapine chemoprophylaxis. All 4 infants had NNRTI-resistant variants other than the K103N mutation. The fifth infant had the M184V mutation. Drug-resistant virus was archived in the resting CD4 + T cell latent reservoir in all 5 infants. Conclusions. The high rate, types, and early archiving of drug-resistant HIV-1 suggests that resistance testing be considered for infants, especially when an NNRTI-based regimen is planned. Furthermore, drug-resistance outcomes in infants should be an important secondary end point in MTCT trials.",
author = "Deborah Persaud and Paul Palumbo and Carrie Ziemniak and Jie Chen and Ray, {Stuart Campbell} and Michael Hughes and Peter Havens and Murli Purswani and Gaur, {Aditya H.} and Chadwick, {Ellen Gould}",
year = "2007",
month = "5",
day = "15",
doi = "10.1086/513871",
language = "English (US)",
volume = "195",
pages = "1402--1410",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States

AU - Persaud, Deborah

AU - Palumbo, Paul

AU - Ziemniak, Carrie

AU - Chen, Jie

AU - Ray, Stuart Campbell

AU - Hughes, Michael

AU - Havens, Peter

AU - Purswani, Murli

AU - Gaur, Aditya H.

AU - Chadwick, Ellen Gould

PY - 2007/5/15

Y1 - 2007/5/15

N2 - Background. The extent to which drug-resistant human immunodeficiency virus type 1 (HIV-1) acquired through mother-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservoirs and limits responses to antiretroviral treatment in infants is unknown. Methods. We evaluated the presence, type, and persistence of drug-resistant HIV-1 in pretreatment plasma and resting CD4+ T cells from US infants enrolled in a multicenter, open-label, phase 1/2 treatment trial of lopinavir/ritonavir (Pediatric AIDS Clinical Trials Group Protocol 1030) in young infants. Results. Twenty-two consecutively enrolled infants initiating highly active antiretroviral therapy at a median age of 9.7 weeks and treated for up to 96 weeks were studied. Drug-resistant HIV-1 was present in 5 (23.8%) of 21 infants analyzed; 4 (80.0%) had nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1, only 1 of whom had a history of receiving nevirapine chemoprophylaxis. All 4 infants had NNRTI-resistant variants other than the K103N mutation. The fifth infant had the M184V mutation. Drug-resistant virus was archived in the resting CD4 + T cell latent reservoir in all 5 infants. Conclusions. The high rate, types, and early archiving of drug-resistant HIV-1 suggests that resistance testing be considered for infants, especially when an NNRTI-based regimen is planned. Furthermore, drug-resistance outcomes in infants should be an important secondary end point in MTCT trials.

AB - Background. The extent to which drug-resistant human immunodeficiency virus type 1 (HIV-1) acquired through mother-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservoirs and limits responses to antiretroviral treatment in infants is unknown. Methods. We evaluated the presence, type, and persistence of drug-resistant HIV-1 in pretreatment plasma and resting CD4+ T cells from US infants enrolled in a multicenter, open-label, phase 1/2 treatment trial of lopinavir/ritonavir (Pediatric AIDS Clinical Trials Group Protocol 1030) in young infants. Results. Twenty-two consecutively enrolled infants initiating highly active antiretroviral therapy at a median age of 9.7 weeks and treated for up to 96 weeks were studied. Drug-resistant HIV-1 was present in 5 (23.8%) of 21 infants analyzed; 4 (80.0%) had nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1, only 1 of whom had a history of receiving nevirapine chemoprophylaxis. All 4 infants had NNRTI-resistant variants other than the K103N mutation. The fifth infant had the M184V mutation. Drug-resistant virus was archived in the resting CD4 + T cell latent reservoir in all 5 infants. Conclusions. The high rate, types, and early archiving of drug-resistant HIV-1 suggests that resistance testing be considered for infants, especially when an NNRTI-based regimen is planned. Furthermore, drug-resistance outcomes in infants should be an important secondary end point in MTCT trials.

UR - http://www.scopus.com/inward/record.url?scp=34248165997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248165997&partnerID=8YFLogxK

U2 - 10.1086/513871

DO - 10.1086/513871

M3 - Article

C2 - 17436219

AN - SCOPUS:34248165997

VL - 195

SP - 1402

EP - 1410

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 10

ER -